Trending Topic

3D rendered Medical Illustration of Male Anatomy - Rectal Cancer.
14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2022

Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the further investigations that are needed to optimise the use of pembrolizumab in this treatment setting.

The abstract entitled ‘Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048‘ Abstract 659MO, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What did the KEYNOTE-048 study teach us about the efficacy and safety of pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma? (0:14)
  2. What have been the study findings at 5 years, and what is their clinical significance? (1:26)
  3. What further investigations are needed to optimise the use of pembrolizumab in this treatment setting? (1:51)

Disclosures: Makoto Tahara is an Advisory board member for Ono Pharmaceutical, BMS, Bayer, MSD, Eli Lilly, GSK, Pfizer, AstraZeneca, Rakuten Medical and Merck Biopharma; and receives honoraria/honorarium from Ono Pharmaceutical, BMS, Bayer, MSD, Eli Lilly, Rakuten Medical and Merck Biopharma.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more head and neck cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup